APG777
Sponsors
Apogee Therapeutics Inc., Apogee Therapeutics, Inc.
Conditions
AsthmaAtopic Dermatitis
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
Active, not recruitingNCT06920901
Start: 2025-03-27End: 2027-03-01Updated: 2026-02-17
An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis
Active, not recruitingNCT07027527
Start: 2025-06-04End: 2027-12-01Updated: 2026-09-08
Phase 2
A Study Evaluating APG777 in Atopic Dermatitis
Active, not recruitingNCT06395948
Start: 2024-04-29End: 2028-06-01Updated: 2026-09-10
A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients with Moderate-to-severe Atopic Dermatitis
Active, not recruitingCTIS2024-511260-84-00
Start: 2024-09-03Target: 163Updated: 2025-12-18
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
RecruitingNCT07003425
Start: 2025-05-14End: 2029-12-01Target: 350Updated: 2026-09-08
APG777-202 - A Long-term Extension Study to Evaluate the Safety and Efficacy of APG777 in Patients With Atopic Dermatitis Previously Treated With APG777
RecruitingCTIS2024-519795-11-00
Start: 2025-10-06Target: 91Updated: 2026-01-15